Boehringer Ingelheim, Inventiva Collaborate to Find New Idiopathic Pulmonary Fibrosis Treatments - Pulmonary Fibrosis News

Boehringer Ingelheim, Inventiva Collaborate to Find New Idiopathic Pulmonary Fibrosis Treatments

Boehringer Ingelheim, Inventiva Collaborate to Find New Idiopathic Pulmonary Fibrosis Treatments - Pulmonary Fibrosis News

Boehringer Ingelheim Announces Several Idiopathic Pulmonary Fibrosis Presentations at Upcoming International Scientific Meeting Pulmonary Fibrosis News

Boehringer Ingelheim Announces Several Idiopathic Pulmonary Fibrosis Presentations at Upcoming International Scientific Meeting

The secondary endpoints for efficacy, safety and immunogenicity of BI 695501 vs. Humira, were also met.

Read more about musician Joe Nichols joining with Boehringer Ingelheim in its campaign to raise awareness about IPF.

Country Music Star Joe Nichols Shares His Dad’s IPF Story in ‘Breathless,’ a Public Awareness Campaign

Read about how Country Music Artist Joe Nichols and Boehringer Ingelheim Pharmaceuticals Launch Breathless™, a Campaign to Raise Awareness for IPF

Read about Boehringer Ingelheim’s OFEV (nintedanib) IPF therapy that saw its efficacy and safety profile reinforced in new studies.

Boehringer Ingelheim’s OFEV (Nintedanib) IPF Therapy Reinforces Efficacy and Safety Profile in New Studies

Read about Boehringer Ingelheim’s OFEV (nintedanib) IPF therapy that saw its efficacy and safety profile reinforced in new studies.

Boehringer Ingelheim Presents Positive data on Idiopathic Pulmonary Fibrosis Therapy OFEV at ATS Conference Pulmonary Fibrosis News

Boehringer Ingelheim Presents Positive Data on Idiopathic Pulmonary Fibrosis Therapy OFEV at ATS Conference

Boehringer Ingelheim Presents Positive data on Idiopathic Pulmonary Fibrosis Therapy OFEV at ATS Conference Pulmonary Fibrosis News

European Regulators Grant Boehringer’s Nintedanib Accelarated Assessment

Scottish Medicines Consortium Recommends Boehringer’s Trajenta - Regulatory Professionals

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim, Architecture, Interior, Projects, Google Search, Ideas

Boehringer Ingelheim Announces Spiolto Respimat Availability in Europe for COPD COPD News Today

Boehringer Ingelheim Announces Spiolto Respimat Availability in Europe for COPD

Ibrahim Schneidawind Group AG® additionally offers an all-encompassing business reporting service to clients in order to help them optimise their investment portfolios.

Boehringer Ingelheim to Present New Data for COPD, IPF and Asthma at European Respiratory Society International Congress Lung Disease News

Boehringer Ingelheim to Present New Data for COPD, IPF and Asthma at European Respiratory Society International Congress

Boehringer Ingelheim to Present New Data for COPD, IPF and Asthma at European Respiratory Society International Congress Lung Disease News

The use of the printed page to reveal the uniformity of migraine scotomas. Left to right: from Jolly (1902); from Gowers (1904); exhibit from the first exhibition of migraine art, from Wilkinson and Robinson, 1985, reproduced with permission of the Migraine Action Association and Boehringer Ingelheim UK Limited.

Exploring the visual hallucinations of migraine aura: the tacit contribution of illustration

boehringer-ingelheim-cares-foundation-giving-report by Boehringer Ingelheim Pharmaceuticals, Inc. via Slideshare

Boehringer Ingelheim Cares Foundation's first online Giving Report. The Giving Report summarizes through short stories, pictures and videos the four primary wa…

<span class="entry-title">Boehringer Ingelheim’s OFEV (Nintedanib) IPF Therapy Reinforces Efficacy and Safety Profile in New Studies</span><span class="entry-subtitle">Post-marketing surveillance analysis confirms OFEV’s safety profile and long-term efficacy</span>

Boehringer Ingelheim’s OFEV (Nintedanib) IPF Therapy Reinforces Efficacy and Safety Profile in New Studies

<span class="entry-title">Boehringer Ingelheim’s OFEV (Nintedanib) IPF Therapy Reinforces Efficacy and Safety Profile in New Studies</span><span class="entry-subtitle">Post-marketing surveillance analysis confirms OFEV’s safety profile and long-term efficacy</span>

Read about FDA's approval of sNDA for Boehringer Ingelheim Pharmaceuticals’ STIOLTO RESPIMAT for improvement of the quality of life for COPD patients.

Stiolto Respimat for COPD Granted FDA's Supplemental NDA Approval

Read about FDA's approval of sNDA for Boehringer Ingelheim Pharmaceuticals’ STIOLTO RESPIMAT for improvement of the quality of life for COPD patients.

Read about collaboration between the Pulmonary Fibrosis Foundation (PFF) and Boehringer Ingelheim to advance PF research and patient care.

PF Foundation and Boehringer Partner to Advance Research, Aid Patients

Find & buy Shaking Hands photos, illustrations or vectors from the high quality stock image collections on Shutterstock.

Boehringer Ingelheim Pharmaceuticals

Leading organizations know that improved employee wellbeing not only helps people to be healthier and lowers healthcare costs, it also helps them to be more productive, creative and innovative, and less likely to leave for a competitor.

Read about findings from the first year of a national idiopathic pulmonary fibrosis registry in Sweden, indicating a low quality of life among patients.

IPF Patients in New Swedish Registry Report Low Quality of Life Even with Moderate Disease

Read about findings from the first year of a national idiopathic pulmonary fibrosis registry in Sweden, indicating a low quality of life among patients.

Pinterest
Search